# Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion

> **NCT01518881** · PHASE1 · TERMINATED · sponsor: **Arbutus Biopharma Corporation** · enrollment: 24 (actual)

## Conditions studied

- Ebola Virus Infection

## Interventions

- **DRUG:** TKM-100201
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01518881
- **Lead sponsor:** Arbutus Biopharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-01
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Corporate decision to reformulate the investigational product.
- **Last updated:** 2014-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01518881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01518881, "Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT01518881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*